One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions
Open Access
- 6 February 2012
- Vol. 67 (4), 462-476
- https://doi.org/10.1111/j.1398-9995.2012.02785.x
Abstract
Allergen immunotherapy was introduced by Leonard Noon 100 years ago and is the only disease‐modifying treatment for allergic individuals. Improved understanding of immunology has taught us a great deal about the underlying mechanisms involved in allergen immunotherapy; however, despite these developments, a number of important questions remain unanswered. Several of these questions relate to the practice of allergen immunotherapy in the clinic, such as: Is it possible to unify units of allergen potency? Which treatment schedules are best? Is allergen immunotherapy effective in all patient groups? Is there a dose–response relationship for efficacy and safety?, and Is there evidence for long‐term effects following allergen immunotherapy? Others are related to new developments, such as new indications, or developments in the production of allergens. On the centenary of Noon's discovery, European experts in the field of immunotherapy met in Geneva under the aegis of the EAACI to discuss these controversial issues. This study presents outcomes and conclusions from these discussions.Keywords
This publication has 89 references indexed in Scilit:
- European Academy of Allergy and Clinical Immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’Allergy, 2011
- A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreSJournal of Allergy and Clinical Immunology, 2011
- Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitizationJournal of Allergy and Clinical Immunology, 2011
- Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergyThe Journal of Experimental Medicine, 2009
- Clinical efficacy and immune regulation with peanut oral immunotherapyJournal of Allergy and Clinical Immunology, 2009
- Safety of a peanut oral immunotherapy protocol in children with peanut allergyJournal of Allergy and Clinical Immunology, 2009
- Grading quality of evidence and strength of recommendations in clinical practice guidelinesAllergy, 2009
- Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trialProceedings of the National Academy of Sciences of the United States of America, 2008
- Hyposensitization in nickel allergic contact dermatitis: Clinical and immunologic monitoringJournal of the American Academy of Dermatology, 1995
- Oral hyposensitization in nickel allergyJournal of the American Academy of Dermatology, 1987